| Identification | |
| Name: | 7-36-Glucagon-likepeptide I (human), 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide- |
| Synonyms: | BIM 51077;ITM 077; R 1583; RO 5073031; Taspoglutide |
| CAS: | 275371-94-3 |
| Molecular Formula: | C152H232 N40 O45 |
| Molecular Weight: | 3339.75 |
| Molecular Structure: |  |
| Properties | |
| Density: | 1.46 |
| Specification: |
Taspoglutide (CAS NO.275371-94-3), its Synonyms are 7-36-Glucagon-like peptide I (human), 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide- ; H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2 . Taspoglutide is a glucagon-like peptide-1 analog drug under investigation for treatment of type 2 diabetes being co-developed by Ipsen and Roche. |
| Safety Data | |
 |
|
